Jose Garcia-Vargas - Bayer Whippany NJ

基本信息

浏览量：45

职业迁徙

个人简介

Oncology clinical developer with more than 20 years Industry experience, qualifications in Radiation and Medical Oncology and expertise in Genitourinary and Breast Cancers, 2 NDA's and working on the next.

研究兴趣

论文共 64 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and Antitumor Activity of Copanlisib in Japanese Patients with Relapsed/refractory Indolent Non-Hodgkin Lymphoma: a Phase Ib/II Study

Noriko Fukuhara,Dai Maruyama,Kiyohiko Hatake,Hirokazu Nagai,Shinichi Makita,Kenjiro Kamezaki,Toshiki Uchida,Shigeru Kusumoto,Junya Kuroda,Chisako Iriyama,Masamitsu Yanada,Norifumi Tsukamoto,Youko Suehiro,Hironobu Minami,Jose Garcia-Vargas,Barrett H. Childs,Masanobu Yasuda, Shigeo Masuda,Toshiaki Tsujino, Yui Terao,Kensei Tobinai

INTERNATIONAL JOURNAL OF HEMATOLOGYno. 1 (2023): 100-109

引用0浏览0WOS引用

Final Safety and Efficacy Results of Copanlisib Monotherapy in Patients with Relapsed or Refractory Inhl: 6‐year Follow‐up of CHRONOS‐1

ONCOLOGY RESEARCH AND TREATMENT (2023): 51-52

引用0浏览0引用

Six-year Safety and Efficacy Results from the CHRONOS-1 Study of the PI3K Inhibitor Copanlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Martin H. Dreyling,Armando Santoro,Sirpa Leppa,Judit Demeter,George Follows,Georg Lenz,Won Seog Kim,Luigina Mollica,Arnon Nagler,Colin Phipps Diong, Mariano Provencio, Massimo Magagnoli, Atanas Radinoff, Javier Munoz, Anjun Cao,Florian Hiemeyer, Fatuma Odongo,Jose E. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani

JOURNAL OF CLINICAL ONCOLOGY（2023）

引用5浏览0引用

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani,Muhit Ozcan,Marcelo Capra,Armando Santoro,Panayiotis Panayiotidis,Krimo Bouabdallah,Wojciech Jurczak,Charles Phelps,Florian J. R. Hiemeyer,Lidia Mongay Soler,Jose Garcia-Vargas,Barrett H. Childs,Georg Lenz,Matthew J. Matasar,Martin Dreyling

Blood（2022）

引用0浏览0引用

A Phase I Pharmacokinetic Study of Copanlisib in Chinese Patients with Relapsed Indolent Non-Hodgkin Lymphoma

Liu Weiping,Ping Lingyan,Xie Yan,Sun Yingli,Du Tingting, Niu Yi,Cisternas Galia,Huang Funan,Garcia-Vargas Jose,Childs Barrett H.,Mehra Aruna,Reschke Susanne,Wang Xiaopei,Song Yuqin,Zhu Jun

Cancer chemotherapy and pharmacology（2022）

引用4浏览0WOS引用

Efficacy and Safety of Copanlisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

Panayiotis Panayiotidis,George A. Follows,Luigina Mollica,Arnon Nagler,Muhit Ozcan,Armando Santoro,Don Stevens,David Trevarthen,Florian Hiemeyer,Jose Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani,Martin Dreyling

Blood advances（2021）

引用18浏览0WOS引用

260P A Phase I Study of Copanlisib, a Pan-Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, in Chinese Patients with Relapsed Indolent Non-Hodgkin Lymphoma (Inhl)

Y. Song,W. Liu,Y. Niu,G. Cisternas,F. Huang,J. Garcia-Vargas,B. H. Childs,A. Mehra, T. Li,F. Hiemeyer,J. Zhai,S. Reschke,C. Granvil, J. Zhu

Annals of oncology（2020）

引用2浏览0引用

COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

Martin Dreyling,Panayiotis Panayiotidis,George A. Follows,Luigina Mollica,Arnon Nagler,Muhit Ozcan,Armando Santoro,Don Stevens,David Trevarthen,Florian Hiemeyer,Li Liu,Jose Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani

BLOOD（2019）

引用3浏览0引用

SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS‐1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA

P.L. Zinzani,A. Santoro,S. Leppä,J. Demeter,G.A. Follows,G. Lenz,W.S. Kim,L. Mollica,A. Nagler,C. Phipps Diong,M. Provencio,M. Magagnoli,J. Munoz,A. Miriyala,L. Liu, M. Zhang,J. Garcia‐Vargas,B.H. Childs,M. Dreyling

Hematological oncologyno. S2 (2019): 389-390

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn